Three trials in 93 patients with metastatic melanoma treated with autologous TIL therapy plus IL-2 infusion showed overall response rates between 49% and 72%, with durable responses in 19 patients.97,102 A phase I trial of TIL therapy in heavily pre-treated patients with melanoma is ongoing, and the regimen has shown safety including in patients with prior anti-PD-1 exposure.99 Computational methods to better define neoepitopes may enable TIL therapy in less inflamed tumors.104. This evidence concerns the gene PDCD1 and melanoma.